Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Philogen SpA ( (IT:PHIL) ) has provided an update.
Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 8,199 shares, representing 0.0202% of its share capital, for a total of Euro 162,240.01 between March 31 and April 4, 2025. This move is part of a broader strategy to manage its capital structure, with the company having acquired a total of 49,656 shares since the program’s inception. The buyback program reflects Philogen’s commitment to enhancing shareholder value and optimizing its financial resources.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology company specializing in the research and development of pharmaceutical products targeting high-mortality diseases. The company focuses on creating targeted anti-cancer drugs using high-affinity ligands for tumor markers, primarily through tumor targeting and vascular targeting strategies. Philogen aims to develop and commercialize innovative treatments for diseases lacking satisfactory therapies, leveraging proprietary technologies, drug development expertise, and a robust portfolio of patents.
YTD Price Performance: 1.05%
Average Trading Volume: 229
Technical Sentiment Signal: Strong Sell
Current Market Cap: €581.9M
For an in-depth examination of PHIL stock, go to TipRanks’ Stock Analysis page.